Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810542 | 0.94 | MEN1 (0.36) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1808693 | 0.86 | MEN1 (0.35) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL23360936 | 0.81 | MEN1 (0.36) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1806236 | 0.80 | MEN1 (0.35) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1811988 | 0.79 | MEN1 (0.38) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1817102 | 0.78 | MEN1 (0.33) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL27547005 | 0.78 | IMPDH2 (0.33) | ALDH1A1 | |
| SCHEMBL22042201 | 0.77 | MEN1 (0.32) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL809345 | 0.77 | VCP (0.33) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL6867251 | 0.74 | MEN1 (0.35) | MEN1ALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078571-B2 | Preparation of 1,3-di-halo-substituted benzene derivatives | CLARIANT GMBH (DE) | 2006-07-18 | — | — | US | claimed |
| US-20040087816-A1 | Preparation of 1,3-di-halo-substituted benzene derivatives | CLARIANT GMBH | 2004-05-06 | — | — | US | claimed |
| EP-1413566-A1 | Process for the preparation of 1,3-dihalo substituted benzene derivatives | Clariant GmbH (DE) | 2004-04-28 | — | — | EP | claimed |
| US-7078571-B2 | Preparation of 1,3-di-halo-substituted benzene derivatives | CLARIANT GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20040087816-A1 | Preparation of 1,3-di-halo-substituted benzene derivatives | CLARIANT GMBH | 2004-05-06 | — | — | US | disclosed |
| EP-1413566-A1 | Process for the preparation of 1,3-dihalo substituted benzene derivatives | Clariant GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087816-A1 | Preparation of 1,3-di-halo-substituted benzene derivatives | HAO2, AOC2, AOC3 | MEN1 2613/4885ALDH1A1 299/4885KMT2A 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.